Methyldopa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Methyldopa: From Hypertension to Malignant Hypertensive Renal Disease
One-Sentence Summary
Methyldopa is a centrally-acting antihypertensive agent. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, but this specific prediction is currently supported by 0 clinical trials and 0 publications — it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (no ARTG licence on file; generally known as an antihypertensive agent) |
| Predicted New Indication | Malignant Hypertensive Renal Disease |
| TxGNN Prediction Score | 96.63% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for methyldopa was not captured in this evidence pack. Based on generally known pharmacology, methyldopa is a centrally-acting alpha-2 adrenergic agonist historically used to lower blood pressure. It is not part of a combination product in this record.
The repurposing rationale supplied with the prediction is explicitly weak: the link to malignant hypertensive renal disease is inferred only from methyldopa’s blood-pressure-lowering mechanism, with no supporting trial or published literature — it reflects the TxGNN prediction score alone, not a validated pharmacological or clinical relationship.
Other, lower-ranked candidates in this evidence pack carry somewhat more supporting material (e.g. rank 2 “malignant renovascular hypertension” has 3 literature hits at L4; rank 6 “chronic pulmonary heart disease” has 2 clinical trials and 6 literature hits, including one RCT of methyldopa in hypoxic cor pulmonale). These were not scored as the top prediction but may warrant separate review if this indication is deprioritised.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Methyldopa currently holds no ARTG entries and is not marketed in Australia (0 licences on file).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for malignant hypertensive renal disease is model-score-only (L5) with no clinical trial or literature support, and the drug is not currently marketed in Australia — there is no basis to progress past initial screening.
To proceed, the following is needed:
- TFDA/TGA-approved Product Information (warnings, contraindications) — currently a blocking data gap preventing S1 safety review
- Mechanism-of-action data for methyldopa (currently a data gap affecting mechanistic-link analysis)
- If this indication is not pursued, consider re-evaluating rank 6 “chronic pulmonary heart disease,” which has 2 clinical trials and literature including a direct methyldopa RCT
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.